1. World Health Organization. Antibacterial Agents in Clinical Development. An Analysis of the Antibacterial Clinical Development Pipeline (Including Tuberculosis, World Health Organization, Geneva, 2017).
2. Schütz, C. & Empting, M. Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers. Beilstein J. Org. Chem. 14, 2627–2645 (2018).
3. Kamal, A. A. M. et al. Quorum sensing inhibitors as pathoblockers for Pseudomonas aeruginosa infections: a new concept in anti-infective drug discovery. In Antibacterials (eds Fisher, J. F. et al.) 185–210 (Springer International Publishing, Berlin, 2018).
4. Finch, S., McDonnell, M. J., Abo-Leyah, H., Aliberti, S. & Chalmers, J. D. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12, 1602–1611 (2015).
5. Silva Filho, L. V. R. et al. Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J. Bras. Pneumol. 39, 495–512 (2013).